Latest filing published 04 Aug 2026 for REGENXBIO Inc., €40k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Patrick J. Christmas, listed as senior executive, appears in our data through filings on REGENXBIO Inc. shares, published by SEC (Form 4). In total, 75 filings cover trades dated from 30 June 2017 to 1 August 2026.
Every open-market trade on record is a sale: 34 sales worth €5.5M. Besides market trades, the filings include 19 share grants and 22 option exercises.
The latest filing, published on 4 August 2026, reports a share grant of €40k in REGENXBIO Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations